http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-396728-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed093205f63d134888eec969f54a7c26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 |
| filingDate | 2011-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c4667c6955202f0e8ed28d377736737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b5e312ebe12a46e4e2425a93e56c5d8 |
| publicationDate | 2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-396728-A1 |
| titleOfInvention | Pharmaceutical kit based on gammaglobulin |
| abstract | The pharmaceutical kit based on human normal gammaglobulin consists of two dry compositions placed in two sealed containers. One container contains a dry composition containing a human normal gammaglobulin conjugate with HYNIC in an amount of 1.9 mg to 2.1 mg, where HYNIC is acid 6 -hydrazinopyridine-3-carboxylic acid and 0.02M citrate buffer with a pH in the range of 5.5 to 5.8 with a content of 0.59 mg sodium citrate dihydrate and 1.02 mg citric acid monohydrate of a maximum volume of 0.5 ml. The second container contains the supplementary ligand in the form of tricine in the amount from 0.2 mg to 0.25 mg, where tricine is N- [tris (hydroxymethyl) methyl] glycine, the reducing agent in the form of tin chloride dihydrate from 0.008 mg up to 0.015 mg and a buffered saline solution free of calcium and magnesium, up to a maximum volume of 1 ml. |
| priorityDate | 2011-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.